L-Cells and K-Cells: Where Incretin Hormones Are Made
Incretin Biology
60% of insulin
Up to 60% of the insulin secreted after eating comes from the incretin effect, driven by GLP-1 from L-cells and GIP from K-cells in your gut lining.
Baggio and Drucker, Gastroenterology, 2007
Baggio and Drucker, Gastroenterology, 2007
View as imageEvery time you eat, specialized cells scattered along your intestinal lining detect nutrients and release peptide hormones that prepare your body to handle the incoming glucose. These cells, called L-cells and K-cells, are the source of the two incretin hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Together, they drive the incretin effect, which accounts for up to 60% of the insulin secreted in response to an oral glucose load.[1] Understanding these cells is foundational to understanding why drugs like semaglutide and tirzepatide work. This article is part of a broader look at GLP-1 and GIP: the two incretins and why they matter.
Key Takeaways
- L-cells produce GLP-1 and are concentrated in the distal intestine (ileum and colon), while K-cells produce GIP and are concentrated in the proximal intestine (duodenum and jejunum) (Baggio and Drucker, 2007)
- The incretin effect accounts for up to 60% of the insulin response after an oral glucose load, meaning gut hormones contribute more to post-meal insulin than blood glucose alone (Baggio and Drucker, 2007)
- Only about 5% of enteroendocrine cells co-express both GLP-1 and GIP, meaning L-cells and K-cells are largely distinct populations despite occasional overlap
- L-cells also produce PYY, GLP-2, and oxyntomodulin from the same proglucagon precursor, making them multi-hormone factories
- Physical activity increases L-cell sensitivity to nutrients and enhances gut peptide secretion (Laursen et al., 2026)
- Obesity alters L-cell function: jejunal enteroids from obese individuals show changes in GLP-1 cell characteristics (Osinski et al., 2026)
What Are L-Cells and K-Cells?
L-cells and K-cells are two types of enteroendocrine cells, a class of specialized epithelial cells that make up about 1% of the intestinal lining but collectively form the largest endocrine organ in the body. They are "open-type" cells, meaning they have direct contact with the intestinal lumen on one side and blood vessels on the other, allowing them to sample the contents of the gut and release hormones into the bloodstream.
Baggio and Drucker, in their foundational 2007 review of incretin biology, established the framework that is still used today: K-cells are the primary source of GIP, concentrated in the duodenum and jejunum; L-cells are the primary source of GLP-1, concentrated in the ileum and colon.[1]
However, newer research has complicated this neat division. Studies using single-cell transcriptomics have shown that enteroendocrine cells exist on a spectrum rather than as rigid categories. Some cells in the duodenum co-express both GLP-1 and GIP, though this overlap is rare, approximately 5% of enteroendocrine cells. L-cells themselves are not uniform: their hormone content varies depending on where they sit in the intestine and whether they are in the crypt or on the villus tip.
How L-Cells Sense Nutrients and Release GLP-1
L-cells are equipped with an array of nutrient-sensing receptors that detect different macronutrients arriving in the gut lumen.
Glucose sensing. L-cells express glucokinase and glucose transporters (GLUT1, GLUT2, GLUT3), enabling them to detect rising luminal glucose concentrations. When glucose enters the L-cell through the sodium-glucose cotransporter SGLT1, it triggers depolarization and calcium influx, which drives GLP-1 exocytosis.[1]
Fat sensing. Long-chain fatty acids activate G-protein-coupled receptors GPR40 and GPR120 on L-cells. Short-chain fatty acids (produced by gut bacteria fermenting fiber) activate GPR41 and GPR43. Christiansen et al. demonstrated that short-chain fatty acids directly stimulate GLP-1 and PYY secretion from the isolated perfused rat colon.[2]
Protein sensing. Amino acids and peptide fragments activate calcium-sensing receptors (CaSR) and GPR142 on L-cells, contributing to the protein-induced GLP-1 response.
Bile acid sensing. The bile acid receptor TGR5 on L-cells links bile acid recycling to GLP-1 secretion, connecting liver and gut endocrine functions.
Sebhat et al. showed that combining GPR119 and GPR40 agonists produces synergistic activation of gut enteroendocrine cells, increasing both GLP-1 and GIP secretion beyond what either receptor achieves alone.[3] This multi-receptor activation explains why mixed meals (containing carbohydrates, fats, and proteins together) produce larger incretin responses than any single macronutrient.
How K-Cells Sense Nutrients and Release GIP
K-cells share many of the same nutrient-sensing mechanisms as L-cells but are positioned in the proximal intestine, where they encounter nutrients first. Cheng et al. characterized GIP's role in carbohydrate metabolism and found that GIP acts not only as an insulin secretagogue but also as an appetite regulator, challenging the earlier view that GIP was primarily a metabolic hormone.[4]
GIP release from K-cells occurs rapidly after nutrient ingestion, typically peaking within 15-30 minutes. The proximal location of K-cells means they respond to the initial wave of nutrients entering the duodenum, while L-cell GLP-1 release follows slightly later as nutrients reach the distal intestine.
This sequential timing creates a coordinated incretin response: early GIP primes the pancreas for insulin release, and later GLP-1 sustains and amplifies it. Both hormones are glucose-dependent, meaning they stimulate insulin secretion only when blood glucose is elevated, providing a built-in safety mechanism against hypoglycemia.
Rossi et al. expanded GIP's known biology, reviewing evidence that GIP plays roles in inflammation modulation beyond its classic incretin function.[5] This broader action profile helps explain why tirzepatide, a dual GLP-1/GIP agonist, produces effects beyond what GLP-1-only drugs achieve. For more on how dual-receptor targeting works, see how tirzepatide's dual mechanism differs from single GLP-1 agonists.
L-Cells Are Multi-Hormone Factories
L-cells do not only make GLP-1. The same proglucagon gene that encodes GLP-1 also encodes GLP-2, oxyntomodulin, and glicentin. When L-cells process proglucagon through prohormone convertase 1/3, all of these peptides are released simultaneously.
GLP-2 promotes intestinal growth and nutrient absorption. It is the basis for teduglutide, a GLP-2 analog used to treat short bowel syndrome.
Oxyntomodulin activates both GLP-1 and glucagon receptors. It reduces food intake and increases energy expenditure, making it an active area of obesity drug development.
PYY (peptide YY) is co-secreted by L-cells and acts as a satiety signal. Along with GLP-1, PYY signals to the brainstem to reduce appetite after meals. For more on how these peptides work together to regulate appetite, see the gut-brain axis of blood sugar.
Glicentin is another proglucagon-derived peptide from L-cells whose function is less well characterized but appears to promote intestinal mucosal growth.
This multi-hormone output means that anything that activates L-cells produces a coordinated metabolic response: glucose-dependent insulin secretion (GLP-1), gut repair and adaptation (GLP-2), appetite suppression (GLP-1 + PYY + oxyntomodulin), and modulation of energy expenditure (oxyntomodulin).
What Happens to L-Cells and K-Cells in Obesity
Obesity disrupts enteroendocrine cell function in ways that are still being characterized.
Osinski et al. developed jejunal enteroid cultures from obese human subjects to study GLP-1 cell behavior directly. They found that enteroids from obese individuals showed altered GLP-1 cell characteristics compared to lean controls, providing the first organoid-based model for studying how obesity affects incretin-producing cells at the cellular level.[6]
The incretin effect itself is diminished in type 2 diabetes. People with T2D show reduced GLP-1 secretion after meals and, more prominently, reduced GIP-mediated insulin secretion (GIP resistance at the pancreatic beta cell). This impaired incretin effect is one of the pathological mechanisms that drugs like semaglutide and tirzepatide are designed to overcome, by providing pharmacological levels of incretin receptor activation that exceed what the patient's own L-cells and K-cells can produce.
The beta cell defect in GIP resistance appears to be more severe than the L-cell secretory defect. That is, the pancreas loses its ability to respond to GIP before the gut loses its ability to produce it. This distinction is clinically relevant: it explains why GLP-1 receptor agonists work in advanced type 2 diabetes (since GLP-1 receptor sensitivity is relatively preserved) while GIP receptor activation requires the dual-agonist approach of tirzepatide to produce meaningful insulin secretion in GIP-resistant patients.
Alavi et al. reviewed the rise of multi-target incretin therapeutics, noting that the evolution from GLP-1-only to dual (GLP-1/GIP) and triple (GLP-1/GIP/glucagon) agonists reflects a deepening understanding of how multiple gut hormones cooperate in metabolic regulation.[7]
Exercise, Diet, and L-Cell Adaptation
L-cells are not fixed in their number or sensitivity. Physical activity and dietary composition can modulate their function.
Laursen et al. demonstrated that physical activity promotes gut adaptation, increasing nutrient responsiveness and sensitivity to gut peptides in L-cells.[8] This provides a mechanistic explanation for why exercise improves glucose tolerance beyond its effects on muscle insulin sensitivity: regular physical activity enhances the gut's ability to produce incretin hormones in response to meals.
Dietary fiber also influences L-cell function. Short-chain fatty acids produced by bacterial fermentation of fiber activate GPR41 and GPR43 on colonic L-cells, stimulating GLP-1 secretion even from nutrients that were not directly absorbed.[2] This is one mechanism by which high-fiber diets improve metabolic health.
Bariatric surgery dramatically alters L-cell exposure to nutrients. Roux-en-Y gastric bypass redirects food directly to the distal intestine, exposing L-cells to undigested nutrients earlier and producing dramatically elevated postoperative GLP-1 levels. Holst reviewed the evidence showing that these elevated endogenous GLP-1 levels mediate much of the metabolic improvement seen after bariatric surgery.[9]
The DPP-4 Problem: Why Endogenous Incretins Disappear So Fast
GLP-1 released by L-cells has a half-life of approximately 2 minutes in the bloodstream. GIP from K-cells lasts slightly longer but is similarly degraded within minutes. The enzyme responsible is dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal amino acids from both hormones, rendering them inactive.
This rapid degradation means that despite the gut producing substantial amounts of GLP-1 and GIP after meals, only a fraction of the released hormone reaches target organs in active form. The liver, which sits downstream of the gut via the portal vein, sees the highest concentrations of active incretins. By the time GLP-1 reaches the pancreas through systemic circulation, most has been degraded.
This biological reality shaped the entire field of incretin-based drug development. Two strategies emerged: replace the hormones with degradation-resistant analogs (GLP-1 receptor agonists like semaglutide), or block the degrading enzyme (DPP-4 inhibitors like sitagliptin). Both approaches work, but they produce very different magnitudes of effect because they operate at different points in the system. For more on the DPP-4 mechanism, see how DPP-4 destroys incretins.
Why L-Cell and K-Cell Biology Matters for Drug Development
Understanding the cellular biology of incretin production explains why different drug strategies work, and points toward future approaches.
GLP-1 receptor agonists (semaglutide, liraglutide) bypass L-cells entirely by providing exogenous GLP-1-like activity at pharmacological doses. They work regardless of the patient's own L-cell function.
DPP-4 inhibitors (sitagliptin, saxagliptin) preserve endogenous GLP-1 and GIP by blocking the enzyme that degrades them. Their efficacy depends entirely on the patient's own L-cell and K-cell output. This is why DPP-4 inhibitors are less potent than GLP-1 agonists: they can only amplify what the gut already produces. For more on this mechanism, see how DPP-4 destroys incretins.
Dual GLP-1/GIP agonists (tirzepatide) activate both incretin receptors simultaneously, mimicking what happens when both L-cells and K-cells fire in response to a meal but at pharmacological intensity.
GPR agonists are an emerging strategy that targets the nutrient sensors on L-cells and K-cells directly, stimulating endogenous incretin release.[3] This approach could theoretically produce a more physiological incretin response than injecting external peptides.
Trivedi et al. reviewed the cardiovascular roles of endogenous GLP-1 and GIP, highlighting that the metabolic benefits of incretins extend well beyond glucose control into vascular protection and cardiac function.[10]
Understanding the incretin effect itself is also explored in the incretin effect: why food triggers more insulin than glucose alone.
The Bottom Line
L-cells and K-cells are specialized gut cells that produce the incretin hormones GLP-1 and GIP, which together drive up to 60% of post-meal insulin secretion. L-cells are multi-hormone factories in the distal intestine, while K-cells are GIP producers in the proximal intestine. Obesity impairs their function, exercise enhances it, and the entire class of GLP-1-based diabetes and weight loss drugs was built on understanding these cells. Future drug development may shift from bypassing these cells (as current injectable peptides do) to directly enhancing their natural output.